TACE combined with lenvatinib-pembrolizumab shows improved PFS in intermediate stage liver cancer

ESMO 2024: Optimising the personalisation of prostate cancer treatment

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies

Addition of relatlimab to nivolumab plus platinum-doublet chemo demonstrates improved clinical benefit in NSCLC

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer

NKT2152 demonstrates anti-tumor activity in heavily pretreated advanced clear cell RCC

Patient reported outcomes for telisotuzumab vedotin in c-Met protein overexpressing EGFR WT nonsquamous NSCLC

Nivolumab plus ipilimumab improves efficacy versus standard of care in non-clear-cell renal cell carcinomas

Breastfeeding after breast cancer is safe

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC

Repeat immune checkpoint inhibitor therapy not recommended for aRCC

Intraoperative radiotherapy at Fortis Healthcare Hospital